The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

Mon, 11th Oct 2021 10:59

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Cadence Minerals PLC, up 42% at 24.65 pence, 12-month range 11.1p-32.49p. Receives confirmation from its secured bank creditors that they have obtained approval from their credit committees for the proposed terms of a settlement agreement, paving the way for Cadence to vest an initial 20% in the Amapa iron ore project in Brazil. A joint venture between Cadence and Indo Sino Trade Pte Ltd will own 99.9% of DEV Mineracao SA, the owner of the Amapa project. "Today's announcement is a landmark for Amapa, both in terms of certainty for DEV employees, the wider Amapa community and for Cadence shareholders," says Chair Andrew Suckling.

----------

Reneuron Group PLC, up 31% at 123.80p, 12-month 70p-153.78p. The biotechnology company reports positive data that provides "clear pre-clinical proof-of-concept" that its novel exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases. "These results are a key milestone for our exosome delivery technology, establishing clear proof of concept in vivo, which more accurately imitates conditions for the targeted delivery of key neurological therapeutics into the human brain," says Chief Executive Olav Hellebo.

----------

Feedback PLC, up 16% at 0.8432p, 12-month range 0.6p-1.57p. The medical imaging software company signs memorandum of understanding with Quest Teleradiology Solutions - a teleradiology organisation with customers across India, the UK and throughout Africa - to develop strategic opportunities for Bleepa, its clinical communications platform, in the "large and growing" Indian healthcare market, the UK and internationally.

----------

Oracle Power PLC, up 15% at 0.385p, 12-month 0.3p-0.75p. The natural resources project developer signs non-exclusive co-operation agreement with PowerChina International Group Ltd to jointly develop a green hydrogen production facility in Pakistan. It is targeting 400 megawatt capacity hydrogen plant, with planned output of around 150,000 kilograms per day.

----------

AIM - LOSERS

----------

ASOS PLC, down 11% at 2,474p, 12-month range 2,300p-5,994.95p. The online fashion retailer posts jump in annual profit, but warns on year ahead and announces departure of chief executive. Adjusted pretax profit for the 2022 financial year expected between around GBP110 million to GBP140 million. This is well below the GBP193.6 million registered for the financial year just ended. ASOS shakes up board to "underpin delivery of the next phase of its global growth strategy". CEO Nick Beighton is stepping down after 12 years with ASOS, including six as CEO, and a search is underway for his replacement.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
9 Apr 2019 10:55

ReNeuron Signs Licence Deal For CTX, hRPC Cell Programmes In China

LONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in

Read more
4 Apr 2019 14:19

ReNeuron upbeat on progress in hRPC study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.

Read more
4 Apr 2019 10:32

ReNeuron Shares Rise On Positive Data From Blindness Treatment Trial

LONDON (Alliance News) - Shares rose in ReNeuron Group PLC on Thursday after it reported positive efficacy in a phase one/two clinical trial of its hRPC cell therapy candidate for treating in the

Read more
18 Mar 2019 11:42

ReNeuron Group Starts Dosing Of Second Cohort In hRPC Study

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it started dosing of the second cohort of patients in a phase II study of its hRPC cell therapy candidate in the blindness-causing of in

Read more
18 Mar 2019 11:33

ReNeuron Group begins dosing second cohort in hRPC study

(Sharecast News) - Cell-based therapeutics company ReNeuron Group updated the market on progress with the ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more
20 Feb 2019 09:47

ReNeuron Reports Positive Preliminary Data In US Retinal Trial

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday reported "significant improvement in vision" in the trial of its hRPC cell therapy candidate for retinal disease.ReNeuron

Read more
20 Feb 2019 08:21

ReNeuron storms on 'exciting' eye disease trial success

(Sharecast News) - ReNeuron Group bounded upward on Wednesday after reporting that its cell-based therapy is showing signs that it can improve the sight of patients suffering from retinitis pigmentosa, which causes blindness.

Read more
31 Jan 2019 09:55

ReNeuron upbeat on data around ease of exosome manufacture

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes was being presented at a US forum on the manufacture of cell and gene therapies.

Read more
24 Jan 2019 12:16

ReNeuron Group Reports First Enrolled Patient In Stroke Clinical Trial

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it enrolled the first patient in its US Phase IIb clinical study of CTX stem cell therapy for stroke disability.The study is a 6

Read more
24 Jan 2019 09:46

First patient dosed in latest ReNeuron study of CTX cell therapy

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that the first patient has been treated in the US Phase IIb clinical study of its 'CTX' cell therapy candidate for stroke disability.

Read more
4 Jan 2019 07:59

ReNeuron Group to collaborate with unnamed US biopharmaceutical firm

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has signed a collaboration agreement with an unnamed US-based biopharmaceutical company to explore the use of its exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy, it announced on Friday.

Read more
14 Dec 2018 12:07

ReNeuron narrows losses as development programmes continue

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group issued its interim results for the six months ended 30 September on Friday, reporting a reduced loss for the period of £5.32m, from £9.57m year-on-year.

Read more
7 Dec 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 10 December Photo-Me InternationalHalf Year ResultsHollywood Bowl GroupFull Year

Read more
18 Oct 2018 12:42

Reneuron's stem cell technology could produce cancer-combating cells

(Sharecast News) - New data from a study by Reneuron has encouraged the company that its stem cell technology could be adapted to specifically attack cancerous cells.

Read more
18 Oct 2018 10:54

ReNeuron Reports New Positive Data Relating To CTX Stem Cell Platform

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said its CTX stem cell therapy candidate can be successfully re-programmed to a pluripotent state.Pluripotent state is an embryonic a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.